DE69841015D1 - Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2 - Google Patents

Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2

Info

Publication number
DE69841015D1
DE69841015D1 DE69841015T DE69841015T DE69841015D1 DE 69841015 D1 DE69841015 D1 DE 69841015D1 DE 69841015 T DE69841015 T DE 69841015T DE 69841015 T DE69841015 T DE 69841015T DE 69841015 D1 DE69841015 D1 DE 69841015D1
Authority
DE
Germany
Prior art keywords
hepatitis
intra
polypeptide
shortened
cellular preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69841015T
Other languages
English (en)
Inventor
Michael Hougton
Qui-Lim Choo
Sergio Abrignani
David Chien
Mark Selby
Edward Glazer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of DE69841015D1 publication Critical patent/DE69841015D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/923—Cell culture
DE69841015T 1997-05-06 1998-05-06 Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2 Expired - Lifetime DE69841015D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4567597P 1997-05-06 1997-05-06
PCT/US1998/009097 WO1998050556A2 (en) 1997-05-06 1998-05-06 Intracellular production of hepatitis c e1 and e2 truncated polypeptides

Publications (1)

Publication Number Publication Date
DE69841015D1 true DE69841015D1 (de) 2009-09-10

Family

ID=21939272

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69841015T Expired - Lifetime DE69841015D1 (de) 1997-05-06 1998-05-06 Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2

Country Status (10)

Country Link
US (2) US6521423B1 (de)
EP (1) EP0980434B1 (de)
JP (3) JP4458556B2 (de)
AT (1) ATE437951T1 (de)
AU (1) AU7471698A (de)
CA (1) CA2288374A1 (de)
DE (1) DE69841015D1 (de)
ES (1) ES2328536T3 (de)
HK (1) HK1023143A1 (de)
WO (1) WO1998050556A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066033A1 (en) * 1998-06-18 1999-12-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtha Nd Human Services Surface targeted expression of a modified hepatitis c virus envelope protein
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
CA2389206C (en) 1999-10-27 2011-01-04 Chiron Corporation Activation of hcv-specific t cells
ES2319727T3 (es) * 1999-12-01 2009-05-12 Novartis Vaccines And Diagnostics, Inc. Estimulacion de anticuerpos especificos de hcv.
US7094882B2 (en) 2000-04-21 2006-08-22 Yeda Research And Development Co. Ltd. Growth factor which acts through erb b-4 rtk
CU23244A1 (es) * 2001-07-16 2007-10-17 Ct Ingenieria Genetica Biotech Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) * 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CA2516403C (en) * 2003-01-17 2014-08-12 Aethlon Medical, Inc. Method for removal of viruses from blood by lectin affinity hemodialysis
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
EP1574517A1 (de) * 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 beinhaltend spezifische Disulfidbrücken
EP1602664A1 (de) * 2004-03-08 2005-12-07 Innogenetics N.V. HCV E1 beinhaltend spezifische Disulfidbrücken
EP1783218A4 (de) * 2004-06-25 2009-02-18 Advanced Life Science Inst Inc Hcv-rna mit neuer sequenz
MX2007004662A (es) * 2004-10-18 2007-11-23 Globeimmune Inc Terapia basada en levaduras para infeccion cronica por hepatitis c.
AU2006301846A1 (en) * 2005-10-13 2007-04-19 Akshaya Bio Inc. Chimeric antigen containing hepatitis C virus polypeptide and FC fragment for eliciting an immune response
WO2009076158A1 (en) 2007-12-07 2009-06-18 Novartis Ag Compositions for inducing immune responses
EP2331125A4 (de) 2008-09-19 2013-03-27 Globeimmune Inc Immuntherapie zur für chronische hepatitis-c-virus-infektionen
CA2909586C (en) 2013-05-15 2021-08-31 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1074422C (zh) 1987-11-18 2001-11-07 希龙股份有限公司 制备含有hcv表位的分离多肽的方法
HU225068B1 (en) 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
MC2188A1 (fr) 1989-05-18 1992-09-16 Chiron Corp Diagnostic du nanbv:polynucleotides permettant de depister le virus de l'hepatite c
SK286106B6 (sk) * 1990-11-08 2008-03-05 Novartis Vaccines & Diagnostics, Inc. Spôsob vykonávania imunodiagnostickej skúšky na detekciu protilátky proti vírusu hepatitídy C
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
US6150134A (en) 1994-07-29 2000-11-21 Innogenetics, N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
WO1996004301A2 (en) * 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
CA2195312A1 (en) * 1994-07-29 1996-02-15 Mark Selby Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same

Also Published As

Publication number Publication date
WO1998050556A2 (en) 1998-11-12
AU7471698A (en) 1998-11-27
WO1998050556A3 (en) 1999-02-11
JP2009232863A (ja) 2009-10-15
EP0980434B1 (de) 2009-07-29
JP2008195722A (ja) 2008-08-28
JP4458556B2 (ja) 2010-04-28
EP0980434A1 (de) 2000-02-23
ES2328536T3 (es) 2009-11-13
US7429385B2 (en) 2008-09-30
US6521423B1 (en) 2003-02-18
ATE437951T1 (de) 2009-08-15
US20040001854A1 (en) 2004-01-01
CA2288374A1 (en) 1998-11-12
HK1023143A1 (en) 2000-09-01
JP2002504810A (ja) 2002-02-12

Similar Documents

Publication Publication Date Title
DE69841015D1 (de) Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
BR0013231A (pt) Complexos citocina-anticorpo múltiplos
ATE295416T1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
PT989999E (pt) Composicao anti-tumoral a base de polipeptido imunogenico de localizacao celular modificada
ATE481480T1 (de) Methoden und zusammensetzungen zur herstellung von polypeptiden
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
DE69022559T2 (de) Expression des rekombinanten Tumor-Nekrosisfaktor-Bindungsproteins I (TBP-I).
ATE500323T1 (de) Subtilisin-variante
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
WO2000053761A3 (en) Human cytokine as ligand of the zalpha receptor and uses thereof
DK0759067T3 (da) Transformerende vækstfaktor alfa-H1
ES8500325A1 (es) Procedimiento para la preparacion de proteinas funcionales de uroquinasa humana.
PT1025245E (pt) Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DK1082423T3 (da) Cyclin E2-gener og -proteiner
ES8706827A1 (es) Procedimiento para preparar polipeptidos.
DE69232945D1 (de) BLUTPLAETTCHEN-GPIIIa P1A1 und -P1A2-EPITOPE, IHRE HERSTELLUNG UND VERWENDUNG
EA200000270A1 (ru) КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
BR9713450A (pt) Quimiocinas de mamìfero
PE42695A1 (es) Procedimiento para producir proteina c
DK0708831T4 (da) Celledensitetsforstærkede proteintyrosinphosphataser
ATE260339T1 (de) Antikörper gegen menschliches restrictin
ATE130872T1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.
WO2000070015A3 (fr) Cultures de cellules d'insecte se multipliant a 37°c, leur p rocede d'obtention, et leurs utilisations

Legal Events

Date Code Title Description
8364 No opposition during term of opposition